AU2010300386B2 - Method of calculating a phosphorus-protein ratio - Google Patents

Method of calculating a phosphorus-protein ratio Download PDF

Info

Publication number
AU2010300386B2
AU2010300386B2 AU2010300386A AU2010300386A AU2010300386B2 AU 2010300386 B2 AU2010300386 B2 AU 2010300386B2 AU 2010300386 A AU2010300386 A AU 2010300386A AU 2010300386 A AU2010300386 A AU 2010300386A AU 2010300386 B2 AU2010300386 B2 AU 2010300386B2
Authority
AU
Australia
Prior art keywords
patient
phosphorus
time interval
defined time
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010300386A
Other languages
English (en)
Other versions
AU2010300386A1 (en
Inventor
Frank A. Gotch
Norma J. Ofsthun
Amanda K. Stennett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fresenius Medical Care Holdings Inc
Original Assignee
Fresenius Medical Care Holdings Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fresenius Medical Care Holdings Inc filed Critical Fresenius Medical Care Holdings Inc
Publication of AU2010300386A1 publication Critical patent/AU2010300386A1/en
Application granted granted Critical
Publication of AU2010300386B2 publication Critical patent/AU2010300386B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/62—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving urea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/60—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to nutrition control, e.g. diets
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/11—Automated chemical analysis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/15—Inorganic acid or base [e.g., hcl, sulfuric acid, etc. ]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/16—Phosphorus containing
    • Y10T436/166666—Phosphorus containing of inorganic phosphorus compound in body fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Medical Informatics (AREA)
  • Primary Health Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • External Artificial Organs (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2010300386A 2009-10-01 2010-10-01 Method of calculating a phosphorus-protein ratio Ceased AU2010300386B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27793509P 2009-10-01 2009-10-01
US61/277,935 2009-10-01
PCT/US2010/051155 WO2011041697A1 (en) 2009-10-01 2010-10-01 Method of calculating a phosphorus-protein ratio

Publications (2)

Publication Number Publication Date
AU2010300386A1 AU2010300386A1 (en) 2012-04-12
AU2010300386B2 true AU2010300386B2 (en) 2014-03-20

Family

ID=43037782

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010300386A Ceased AU2010300386B2 (en) 2009-10-01 2010-10-01 Method of calculating a phosphorus-protein ratio

Country Status (5)

Country Link
US (1) US8822225B2 (https=)
EP (1) EP2483685B1 (https=)
JP (1) JP5894533B2 (https=)
AU (1) AU2010300386B2 (https=)
WO (1) WO2011041697A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8845570B2 (en) 2010-04-16 2014-09-30 Baxter International Inc. Therapy prediction and optimization for renal failure blood therapy, especially home hemodialysis
US9132219B2 (en) 2010-04-16 2015-09-15 Baxter International Inc. Therapy prediction and optimization of serum potassium for renal failure blood therapy, especially home hemodialysis
US12159716B2 (en) 2019-04-04 2024-12-03 Kpn Innovations, Llc. Methods and systems for generating an alimentary instruction set identifying an individual prognostic mitigation plan
US12040090B2 (en) 2019-04-04 2024-07-16 Kpn Innovations, Llc. Systems and methods for generating alimentary instruction sets based on vibrant constitutional guidance
US11222727B2 (en) 2019-04-04 2022-01-11 Kpn Innovations, Llc Systems and methods for generating alimentary instruction sets based on vibrant constitutional guidance
US10553316B1 (en) 2019-04-04 2020-02-04 Kpn Innovations, Llc Systems and methods for generating alimentary instruction sets based on vibrant constitutional guidance
US11322255B2 (en) 2019-04-04 2022-05-03 Kpn Innovations, Llc. Methods and systems for self-fulfillment of an alimentary instruction set based on vibrant constitutional guidance
US11315684B2 (en) 2019-04-04 2022-04-26 Kpn Innovations, Llc. Systems and methods for generating alimentary instruction sets based on vibrant constitutional guidance
US11594316B2 (en) 2020-05-04 2023-02-28 Kpn Innovations, Llc. Methods and systems for nutritional recommendation using artificial intelligence analysis of immune impacts
US11875889B2 (en) 2020-05-29 2024-01-16 Kpn Innovations, Llc. Methods and systems of alimentary provisioning
US12009085B2 (en) 2020-07-27 2024-06-11 Kpn Innovations, Llc. Systems and methods for scheduling alimentary combinations
US11393572B2 (en) 2020-11-03 2022-07-19 Kpn Innovations, Llc. System and method for modifying a nutrition requirement

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2884124B2 (ja) * 1992-01-31 1999-04-19 鈴与株式会社 リン吸着剤
US5753706A (en) * 1996-12-16 1998-05-19 Hsu; Chen Hsing Methods for treating renal failure
US20040193446A1 (en) 2003-03-27 2004-09-30 Mayer Steven Lloyd System and method for managing a patient treatment program including a prescribed drug regimen
JP4633552B2 (ja) * 2005-06-22 2011-02-16 株式会社テクノメディカ 腎臓機能コントロール状態測定方法及び測定システム
EP2013829A4 (en) * 2006-05-02 2010-07-07 Proteus Biomedical Inc PERSONALIZED THERAPEUTIC REGIMES FOR A PATIENT

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KUHLMANN, M. K., Hemodialysis International, 2006, Vol. 10, pages 338-345 *

Also Published As

Publication number Publication date
WO2011041697A1 (en) 2011-04-07
US8822225B2 (en) 2014-09-02
EP2483685B1 (en) 2018-09-26
JP2013506845A (ja) 2013-02-28
EP2483685A1 (en) 2012-08-08
JP5894533B2 (ja) 2016-03-30
AU2010300386A1 (en) 2012-04-12
US20120184036A1 (en) 2012-07-19

Similar Documents

Publication Publication Date Title
AU2010300386B2 (en) Method of calculating a phosphorus-protein ratio
Abosaif et al. The outcome of acute renal failure in the intensive care unit according to RIFLE: model application, sensitivity, and predictability
Rodriguez-Benot et al. Mild hyperphosphatemia and mortality in hemodialysis patients
Kestenbaum et al. Parathyroidectomy rates among United States dialysis patients: 1990–1999
Goldenstein et al. Serum bicarbonate concentrations and kidney disease progression in community-living elders: the Health, Aging, and Body Composition (Health ABC) Study
Kloppenburg et al. Assessing dialysis adequacy and dietary intake in the individual hemodialysis patient
AU2009305602B2 (en) Method of determining a phosphorus binder dosage for a dialysis patient
Sabanayagam et al. Serum calcium levels and hypertension among US adults
Reddy et al. Clinical utility of anion gap in deciphering acid–base disorders
Chin et al. Feasibility of incremental 2-times weekly hemodialysis in incident patients with residual kidney function
Salahudeen et al. Impact of lower delivered Kt/V on the survival of overweight patients on hemodialysis
Ino et al. Multidisciplinary team care delays the initiation of renal replacement therapy in diabetes: a five-year prospective, single-center study
Stegeman et al. Determination of protein catabolic rate in patients on chronic intermittent hemodialysis: Urea output measurements compared with dietary protein intake and with calculation of urea generation rate
Uchiyama et al. Spot urine-guided salt reduction in chronic kidney disease patients
Chun-yan et al. Low-dose dialysis combined with low protein intake can maintain nitrogen balance in peritoneal dialysis patients in poor economies
Wilson et al. Xanthinuria in a large kindred
Hegbrant et al. Residual renal phosphate clearance in patients receiving hemodialysis or hemodiafiltration
Chun-yan et al. Peritoneal dialysis can maintain nitrogen balance with low Kt/V in anuric patients
JP2002543386A (ja) ヒト腎臓疾患の診断
Mercadal et al. MON-111 Effect of the dialysate calcium concentration and of the mineral bone disease therapies on mortality in the REIN registry
Marsenic et al. Application of individualized Bayesian urea kinetic modeling to pediatric hemodialysis
Zhang et al. Impact of Continuous Renal Replacement Therapy as Treatment for Sepsis-Associated Acute Kidney Injury on Lactate Levels and the Risk of 28-Day Mortality in Intensive Care Units
Jones et al. Estimation of total daily creatinine clearance in CAPD from serum creatinine concentration
Mohamed et al. Is there a difference between serum Cystatin C and serum creatinine levels before and after hemodialysis in chronic kidney disease children?
Ling et al. A Case of Disappearing Hypertension: Difficulties of Managing Hypertension in a Breast Cancer Survivor: PO2122

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired